The open label, multicenter phase I/II study comprising 20 patients evaluated the tolerability and efficacy of OvaSave, an antigen-specific regulatory T cell-based immunotherapy.
The data demonstrated that OvaSave was well tolerated, where 40% of the patients positively responded five weeks after treatment in the overall population group.
The positive data of this study has led the company to take up the initiation of phase II study in the same patient population.